TCJL37

Cat. No.:	HY-16640
CAS No.:	1258294-34-6
Molecular Formula:	$C_{17}H_{11}ClF_2N_4O_2$
Molecular Weight:	376.74
Target:	JAK
Pathway:	Epigenetics; JAK/STAT Signaling; Stem Cell/Wnt
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	TCJL37 is a potent, selective, and orally bioavailable TYK2 inhibitor with a K_i of 1.6 nM. TCJL37 can be used for the research of inflammatory bowel diseases (IBD)[1].
IC_{50} & Target	Tyk2 1.6 nM (Ki)
In Vitro	In cell-based assays, TCJL37 (Compound 37) shows IL-12 pSTAT4 EC_{50} of 224 nM. TCJL37 shows EC_{50}s of 168 nM and 737 nM In human peripheral blood mononuclear cells (PBMC) and human whole blood assay, respectively[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	TCJL37 exhibits excellent oral exposure in CD-1 mice following oral administration (100 mg/kg). TCJL37 exhibits low clearance (1.0 mL/min/kg) in rat[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Jun Liang, et al. Lead optimization of a 4-aminopyridine benzamide scaffold to identify potent, selective, and orally bioavailable TYK2 inhibitors. J Med Chem. 2013 Jun 13;56(11):4521-36.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA